163 related articles for article (PubMed ID: 36760714)
21. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
22. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
Tyler EM; Jungbluth AA; O'Reilly RJ; Koehne G
Blood; 2013 Jan; 121(2):308-17. PubMed ID: 23160468
[TBL] [Abstract][Full Text] [Related]
23. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
24. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
Liu JJ; Wang ZY; Deuel TF; Xu YH
Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
[TBL] [Abstract][Full Text] [Related]
25. A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia.
Algar E
J Hematother Stem Cell Res; 2002 Aug; 11(4):589-99. PubMed ID: 12201948
[TBL] [Abstract][Full Text] [Related]
26. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
28. Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study.
Charles AK; Mall S; Watson J; Berry PJ
Mol Pathol; 1997 Jun; 50(3):138-44. PubMed ID: 9292148
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of chromosome 11p imbalances in aniridia and Wilms tumor patients.
Busch M; Leube B; Thiel A; Schanze I; Beier M; Royer-Pokora B
Am J Med Genet A; 2013 May; 161A(5):958-64. PubMed ID: 23494989
[TBL] [Abstract][Full Text] [Related]
30. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
Werner H; Roberts CT; Rauscher FJ; LeRoith D
J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Kwon M; Martínez-Laperche C; Infante M; Carretero F; Balsalobre P; Serrano D; Gayoso J; Pérez-Corral A; Anguita J; Díez-Martín JL; Buño I
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1235-42. PubMed ID: 22281301
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
33. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
34. [A case of extramedullary plasmacytoma of testis converted to multiple myeloma].
Matsuda Y; Kato R; Miyao N; Sato S; Konishi Y; Kon S
Hinyokika Kiyo; 2010 Oct; 56(10):593-5. PubMed ID: 21063167
[TBL] [Abstract][Full Text] [Related]
35. The expression of WT1 in the differentiation of rhabdomyosarcoma from other pediatric small round blue cell tumors.
Carpentieri DF; Nichols K; Chou PM; Matthews M; Pawel B; Huff D
Mod Pathol; 2002 Oct; 15(10):1080-6. PubMed ID: 12379755
[TBL] [Abstract][Full Text] [Related]
36. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
37. WT1 mutations may be a cause of severe renal failure due to nephroblastomatosis in Wilms' tumor patients.
Santín S; Fraga G; Ruíz P; Pardo N; Torrent M; Martí T; Ballarín J; Ars E; Torra R
Clin Nephrol; 2011 Sep; 76(3):244-8. PubMed ID: 21888862
[TBL] [Abstract][Full Text] [Related]
38. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
Maiti S; Alam R; Amos CI; Huff V
Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
[TBL] [Abstract][Full Text] [Related]
39. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
40. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
